Table 1.
Performance of the classifier. Performance of the 13 clusters classifier algorithm re-training and validation on the separate institutional populations using both leave-one-out and multiple 10-fold cross-validations.
| Training set (total/events) | Validation set (total/events) | Hazard ratio (95%CI) | Log rank p value | Distant Metastases Free Survival for low risk group only# | ||
| DMFS at 3 years | DMFS at 5 years | DMFS at 10 years | ||||
| OXFT (99/19) | KIT/GUYT(156/48) | 2.17 (1.2–3.91) | <0.00001 | 91% | 87% | 79% |
| KIT (69/20) | OXFT/GUYT (186/47) | 4.07 (2.23–7.41) | <0.00001 | 96% | 92% | 88% |
| GUYT (87/28) | OXFT/KIT (168/39) | 5.93 (3.0–11.75) | <0.00001 | 93% | 89% | 82% |
| KIT/GUYT (156/48) | OXFT (99/19) | 14.59 (5.38–39.5) | <0.00001 | 97% | 94% | 91% |
| OXFT/GUYT (186/47) | KIT (69/20) | 3.44 (1.36–8.67) | 0.005 | 96% | 92% | 84% |
| OXFT/KIT(168/39) | GUYT (87/28) | 2.23 (1.05–4.71) | 0.03 | 96% | 92% | 84% |
| Leave-one-out cross validation (255/67)* | 3.86 (2.32–6.41) | <0.0001 | 94% | 91% | 84% | |
| Multiple 10-fold cross-validation (255/67) | 3.23 (2.66–3.84) | <0.0001 | 94% | 90% | 83% | |
# as estimated by Kaplan Meier survival curves.
Patients samples obtained from: OXFT: John Radcliffe Hospital, Oxford, UK; KIT Uppsala University hospital, Uppsala, Sweden; GUYT Guys hospital, London, UK.
• Reported results.